Follicular lymphoma is a slow-growing blood cancer that arises from B cells in the lymph nodes. It's the second most common type of non-Hodgkin lymphoma in adults, accounting for about one in five cases. Many people live with it for years, sometimes watching without treatment, sometimes going through cycles of treatment and remission.
What's actually going on in research
Trials are testing bispecific antibodies that redirect immune cells to kill lymphoma, CAR T-cell therapy adapted from aggressive lymphoma settings, and combinations that might delay or eliminate the need for chemotherapy. Researchers are also studying maintenance strategies with drugs like lenalidomide, exploring when to treat versus watch, and investigating whether certain genomic markers predict which patients need earlier intervention.
Bispecific antibodies
These engineered proteins link a patient's own T cells directly to lymphoma cells. Mosunetuzumab and epcoritamab are already FDA-approved for relapsed disease, and trials are testing them earlier in treatment.
CAR T-cell therapy
After success in aggressive lymphomas, CAR T is now being studied in follicular lymphoma that has relapsed after several treatments. Early results suggest it may produce long remissions in people who've run out of other options.
Chemotherapy-free regimens
Combinations of targeted drugs and antibodies are being tested as first treatment to see if they can control the disease without traditional chemotherapy. The goal is similar or better results with fewer side effects.
What to know before you search
Eligibility typically depends on how many prior treatments you've had, how recently your lymphoma progressed, and sometimes on specific genetic features of the tumor.
What types of trials are currently open
- Treatment trials — Testing new drugs or combinations, often bispecific antibodies or targeted therapies, to see if they work better than current approaches.
- CAR T trials — Studying whether genetically modified immune cells can produce long-lasting remissions in people whose lymphoma has returned after multiple treatments.
- Maintenance trials — Testing whether continuing treatment with drugs like lenalidomide after initial response can keep the lymphoma under control longer.
- Watch-and-wait studies — Following people with slow-growing lymphoma who don't need immediate treatment to understand when intervention becomes necessary.
- Biomarker studies — Analyzing tissue and blood samples to identify genetic features that predict which patients will do well and which might need more aggressive treatment.
Recently added Follicular Lymphoma trials
Take an experimental immune therapy for B-cell lymphoma
This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02.
Take an immunotherapy drug combined with a standard targeted therapy
Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy)
Find Follicular Lymphoma trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.